Coronavirus disease 2019 (COVID-19) is associated with significant hypercoagulability. However, despite prophylactic anticoagulation, critically ill patients with this condition develop thromboses. This forum discusses the lungs as the epicenter for the hemostatic issues, puts forward a proposal for staging COVID-19 coagulopathy based on available diagnostic markers, and suggest considering current and future treatment options based on these different stages.
No takes yet. Share an insight, caveat, or question.
Thachil et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: